Amylyx Pharmaceuticals Inc (AMLX)
1.93
+0.12
(+6.63%)
USD |
NASDAQ |
May 01, 16:00
1.93
0.00 (0.00%)
Pre-Market: 20:00
Amylyx Pharmaceuticals Cash from Financing (Quarterly): 0.23M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.23M |
| September 30, 2023 | 0.889M |
| June 30, 2023 | 1.384M |
| March 31, 2023 | 1.04M |
| December 31, 2022 | 232.16M |
| September 30, 2022 | 0.00 |
| Date | Value |
|---|---|
| June 30, 2022 | -0.828M |
| March 31, 2022 | 200.46M |
| December 31, 2021 | -1.065M |
| September 30, 2021 | 131.65M |
| June 30, 2021 | 1.993M |
| March 31, 2021 | 25.93M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.065M
Minimum
Dec 2021
232.16M
Maximum
Dec 2022
49.49M
Average
1.212M
Median
Cash from Financing (Quarterly) Benchmarks
| Cassava Sciences Inc | 1.143M |
| iRhythm Technologies Inc | 3.468M |
| Bristol-Myers Squibb Co | 14.64B |
| Moderna Inc | -109.00M |
| ACADIA Pharmaceuticals Inc | 5.434M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 13.55M |
| Cash from Investing (Quarterly) | 20.92M |
| Free Cash Flow | 10.68M |
| Free Cash Flow Per Share (Quarterly) | 0.1898 |
| Free Cash Flow to Equity (Quarterly) | 13.20M |
| Free Cash Flow to Firm (Quarterly) | 13.20M |
| Free Cash Flow Yield | 7.90% |